Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ultragenyx Pharmaceutical (RARE) and Sanofi (SNYNF).
Ultragenyx Pharmaceutical (RARE)
In a report released today, Joseph Schwartz from Leerink Partners maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $178.00. The company’s shares closed last Friday at $150.26.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 20.4% and a 53.2% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Aurinia Pharmaceuticals, and Millendo Therapeutics.
Ultragenyx Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $157.58, representing a 1.2% upside. In a report issued on February 11, Piper Sandler also maintained a Buy rating on the stock with a $170.00 price target.
See today’s analyst top recommended stocks >>
Sanofi (SNYNF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Sanofi, with a price target of EUR70.00. The company’s shares closed last Friday at $93.85.
According to TipRanks.com, Papadakis is a 2-star analyst with an average return of 1.4% and a 57.8% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Sanofi-Aventis Sa, Roche Holding AG, and GlaxoSmithKline.
Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $117.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNYNF:
